Foghorn Therap Rg

Clinical‑stage biopharma Foghorn uses a proprietary Gene Traffic Control platform to target chromatin regulation, developing BRG1/BRM inhibitors and protein degraders for cancers, with strategic alliances to Lilly and Merck.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 112
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
FHTX	Foghorn Therap Rg Cap: 0.3B	EQUITY	NGM	USD	US3441741077	Active	📈